In a report released today, Laura Chico from Wedbush maintained a Buy rating on PepGen Inc. (PEPG – Research Report), with a price target of $21.00. The company’s shares closed yesterday at $7.25.
Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Edgewise Therapeutics, and Neurocrine. According to TipRanks, Chico has an average return of 3.0% and a 49.52% success rate on recommended stocks.
PepGen Inc. has an analyst consensus of Strong Buy, with a price target consensus of $23.50.
See the top stocks recommended by analysts >>
PEPG market cap is currently $172.6M and has a P/E ratio of -2.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PepGen Inc. (PEPG) Company Description:
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.
Read More on PEPG:
